Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The daily Top 10 COVID papers

  Ovarian Neoplasms

  Free Subscription


1 Am J Obstet Gynecol
1 Ann Oncol
1 BMC Cancer
2 Br J Cancer
1 Cancer Chemother Pharmacol
2 Gynecol Oncol
4 Int J Gynecol Pathol
4 Oncol Rep

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Obstet Gynecol

  1. SAMIMI G, Sathyamoorthy N, Tingen CM, Mazloomdoost D, et al
    Report of NCI and NICHD-Sponsored Workshop: Gynecology and Women's Health-Benign Conditions and Cancer.
    Am J Obstet Gynecol. 2020 Aug 21. pii: S0002-9378(20)30877.
    PubMed         Abstract available

    Ann Oncol

  2. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    PubMed         Abstract available

    BMC Cancer

  3. GRIMES MM, Kenney SR, Dominguez DR, Brayer KJ, et al
    The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo.
    BMC Cancer. 2021;21:40.
    PubMed         Abstract available

    Br J Cancer

  4. WINFIELD JM, Wakefield JC, Brenton JD, AbdulJabbar K, et al
    Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01217.
    PubMed         Abstract available

  5. SALAS-BENITO D, Conde E, Tamayo-Uria I, Mancheno U, et al
    The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1(+) tumour-infiltrating lymphocytes.
    Br J Cancer. 2021 Jan 5. pii: 10.1038/s41416-020-01218.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  6. LIU YK, Jia YJ, Liu SH, Ma J, et al
    FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-kappaB pathway.
    Cancer Chemother Pharmacol. 2021 Jan 3. pii: 10.1007/s00280-020-04215.
    PubMed         Abstract available

    Gynecol Oncol

    State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.

  8. HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
    Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
    Gynecol Oncol. 2021;160:187-192.
    PubMed         Abstract available

    Int J Gynecol Pathol

  9. CHAPEL DB, Lengyel E, Ritterhouse LL, Lastra RR, et al
    Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report.
    Int J Gynecol Pathol. 2020;39:233-237.
    PubMed         Abstract available

  10. FAHOUM I, Brazowski E, Hershkovitz D, Aizic A, et al
    Tumor-to-Tumor Metastasis of Colorectal Adenocarcinoma to Ovarian Cystadenofibroma: A Case Report and Review of the Literature.
    Int J Gynecol Pathol. 2020;39:270-272.
    PubMed         Abstract available

  11. ABOZINA A, Singh N, Blake C
    Transtubal Spread of a Superficially Invasive Cervical Adenocarcinoma to the Ovaries After 11 Years.
    Int J Gynecol Pathol. 2020;39:296-300.
    PubMed         Abstract available

  12. MEYDANLI MM, Aslan K, Oz M, Muftuoglu KH, et al
    Is It Possible to Develop a Prediction Model for Lymphovascular Space Invasion in Endometrioid Endometrial Cancer?
    Int J Gynecol Pathol. 2020;39:213-220.
    PubMed         Abstract available

    Oncol Rep

  13. AN Q, Liu T, Wang MY, Yang YJ, et al
    KRT7 promotes epithelialmesenchymal transition in ovarian cancer via the TGFbeta/Smad2/3 signaling pathway.
    Oncol Rep. 2020 Dec 8. doi: 10.3892/or.2020.7886.
    PubMed         Abstract available

  14. BRUM MCM, Dos Santos Guimaraes I, Ferreira LB, Rangel LBA, et al
    Osteopontinc isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
    Oncol Rep. 2020 Dec 1. doi: 10.3892/or.2020.7877.
    PubMed         Abstract available

  15. WEI L, He Y, Bi S, Li X, et al
    miRNA199b3p suppresses growth and progression of ovarian cancer via the CHK1/Ecadherin/EMT signaling pathway by targeting ZEB1.
    Oncol Rep. 2020 Dec 11. doi: 10.3892/or.2020.7895.
    PubMed         Abstract available

  16. ZHAO L, Liu Z, Deng X, Wang J, et al
    Polyphyllin VII induces mitochondrial apoptosis by regulating the PP2A/AKT/DRP1 signaling axis in human ovarian cancer.
    Oncol Rep. 2020 Dec 2. doi: 10.3892/or.2020.7879.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.